HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
Long-term benefits of switching to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001
Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Clinical efficacy of seretide and beclomethasone dipropionate in patients with corticosteroid-dependent bronchial asthma and quality of life Source: Eur Respir J 2004; 24: Suppl. 48, 285s Year: 2004
Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
HFA vs CFC beclomethasone dipropionate – comparative effectiveness in asthma management Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006
The clinical effectiveness of HFA-beclomethasone dipropionate in children with moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 166s Year: 2004
QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Nebulized beclomethasone dipropionate is as effective and as well tolerated than nebulized budesonide to prevent asthma exacerbations in infants Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001
Use of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) extrafine aerosol in optimising the management of allergic bronchopulmonary aspergillosis (ABPA) Source: Eur Respir J 2003; 22: Suppl. 45, 237s Year: 2003
Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007
Inhalation of beclomethason dipropionate spray compared with theophilline as primary treatment for chronic mild-to-moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
Efficacy, safety and cost of using beclomethason dipropionate in patients with persistent moderate bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004
Real-life effectiveness of beclomethasone diproprionate/formoterol extra-fine combination in adult patients with persistent asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011
Extrafine beclomethasone dipropionate aerosol therapy shows promising improved effect in treatment of children with stable asthma Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009